Pharmacological properties of a new potential neuroleptic drug oxyprothepin. IV. Antiadrenergic action and influence on brain monoamines.
D000818:Animals; D001058:Apomorphine / Q000037:antagonists & inhibitors; D001522:Behavior, Animal / Q000187:drug effects; D001923:Brain Chemistry / Q000187:drug effects*; D002746:Chlorpromazine / Q000494:pharmacology; D003988:Dibenzothiepins / Q000494:pharmacology*; D004285:Dogs; D004298:Dopamine / Q000378:metabolism; D004347:Drug Interactions; D004837:Epinephrine / Q000037:antagonists & inhibitors; D005247:Feeding Behavior / Q000187:drug effects*; D008124:Locomotion / Q000187:drug effects; D008409:Mastication / Q000187:drug effects; D051379:Mice; D009638:Norepinephrine / Q000037:antagonists & inhibitors / Q000378:metabolism; D010633:Phenmetrazine / Q000037:antagonists & inhibitors; D010830:Physostigmine / Q000037:antagonists & inhibitors; D010879:Piperazines / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D012701:Serotonin / Q000378:metabolism; D014149:Tranquilizing Agents / Q000494:pharmacology*; D014839:Vomiting / Q000139:chemically induced
D003988:Dibenzothiepins; D010879:Piperazines; D014149:Tranquilizing Agents; D012701:Serotonin; D010830:Physostigmine; D001058:Apomorphine; D002746:Chlorpromazine; D004298:Dopamine; D009638:Norepinephrine; D010633:Phenmetrazine; D004837:Epinephrine